PMID- 38470213
OWN - NLM
STAT- MEDLINE
DCOM- 20240408
LR  - 20240408
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 23
IP  - 4
DP  - 2024 Apr
TI  - Dupilumab in real-life settings: a review of adverse events and their 
      pathogenesis.
PG  - 439-447
LID - 10.1080/14740338.2024.2326480 [doi]
AB  - INTRODUCTION: Dupilumab is a safe and effective biological drug that 
      revolutionized the treatment of atopic dermatitis (AD). Concerning adverse events 
      (AEs), the most commonly reported included ocular involvement, nasopharyngitis, 
      and injection site reactions in clinical trials. Anyway, its use in daily 
      practice is revealing novel dupilumab-induced manifestations. AREAS COVERED: 
      Relevant English literature (real-life studies, case series, reviews, and 
      meta-analyses) regarding real-life adverse events induced by dupilumab were 
      searched for up to 10 June 2023. EXPERT OPINION: Dupilumab is an effective 
      treatment for AD, showing favorable safety profile since no routine laboratory 
      monitoring is recommended. However, several cutaneous and extracutaneous AEs have 
      been reported in real-life setting expanding the pool emerged from clinical 
      trials. In detail, dupilumab may determine de-novo onset or exacerbation of 
      preexisting conditions, whose pathogenesis is still unclear and seems to involve 
      Th1/Th2 and Th2/Th17 immune-response imbalance. Also, the heterogeneity and the 
      variable onset time of AEs with respect to dupilumab initiation warrant a 
      thorough patients' history collection and strict short- and long-term monitoring. 
      Finally, the most appropriate management of patients with AEs related to 
      dupilumab should take into consideration efficacy for AD as well as severity and 
      nature of the AE, available treatment and patients' preferences.
FAU - Camela, Elisa
AU  - Camela E
AUID- ORCID: 0000-0001-7201-9163
AD  - Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
FAU - Giampetruzzi, Anna Rita
AU  - Giampetruzzi AR
AD  - Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
FAU - De Pita, Ornella
AU  - De Pita O
AD  - Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
FAU - Pallotta, Sabatino
AU  - Pallotta S
AUID- ORCID: 0000-0003-4827-2892
AD  - Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
FAU - Russo, Filomena
AU  - Russo F
AUID- ORCID: 0000-0003-2780-7720
AD  - Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240312
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 420K487FSG (dupilumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Antibodies, Monoclonal, Humanized
MH  - *Dermatitis, Atopic/drug therapy
MH  - Administration, Cutaneous
MH  - Injections, Subcutaneous
MH  - Treatment Outcome
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Adverse event
OT  - dupilumab
OT  - pathogenesis
OT  - real-life
OT  - safety
EDAT- 2024/03/12 12:43
MHDA- 2024/04/08 06:43
CRDT- 2024/03/12 09:43
PHST- 2024/04/08 06:43 [medline]
PHST- 2024/03/12 12:43 [pubmed]
PHST- 2024/03/12 09:43 [entrez]
AID - 10.1080/14740338.2024.2326480 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2024 Apr;23(4):439-447. doi: 10.1080/14740338.2024.2326480. 
      Epub 2024 Mar 12.